Peptic Ulcer: Symptoms, Diagnosis, Treatment & Red Flags

Peptic ulcer disease refers to acid-peptic injury that erodes through the muscularis mucosae of the stomach or proximal duodenum, creating a discrete crater with surrounding inflammation and granulation tissue. Hydrogen ion, pepsin and often bile reflux perpetuate tissue breakdown until defensive factors—mucus-bicarbonate, mucosal blood flow, epithelial restitution and prostaglandin-regulated homeostasis—are overwhelmed.

Helicobacter pylori neutralises gastric acid locally, disrupts tight junctions and triggers cytokine-mediated inflammation, whereas cyclooxygenase-inhibiting drugs (traditional NSAIDs, partly selective agents and aspirin) lower protective prostaglandins. Glucocorticoids rarely cause ulcers alone yet amplify risk when combined with NSAIDs. ICU-associated stress injury reflects splanchnic hypoperfusion and acid hypersecretion in critically ill patients. A small fraction traces to gastrin-driven hyperacidity requiring exclusion of gastrinoma when ulcers resist standard therapy or cluster atypically.

Nurses interpret peptic disease as a dynamic balance between aggression and defence: healing follows when the inciting factor is removed (eradication, NSAID cessation, risk mitigation) and when sustained acid suppression permits epithelial re-generation. Failure to heal or early relapse flags non-adherence, persistent H. pylori, ongoing NSAID exposure, malignancy masquerading as gastric ulcer or alternate diagnoses such as Crohn disease and ischaemia.

Gastric vs duodenal signals: Classic teaching holds that gastric ulcer pain worsens with meals while duodenal ulcer pain improves briefly after eating and returns hours later—real patients blur these patterns, so endoscopy remains decisive. Because gastric ulcers share endoscopic appearance with early malignancy, guidelines emphasise biopsy of the rim and crater base and endoscopic documentation of healing.

Forrest classification (bleeding stigmata): Endoscopists label ulcers by active bleeding or stigmata of recent haemorrhage to drive prognosis and therapy. High-risk lesions (active spurting, visible vessels, adherent clots after targeted washing) demand endoscopic haemostasis plus adjunctive high-dose PPI protocols; clean-based ulcers are lower risk but still need observation and secondary prevention planning.

↔On a small screen, swipe or scroll sideways to see the full table.

Document exact Forrest language from the procedure note—paraphrasing loses fidelity during handoffs to night teams.

Peptic ulcers often masquerade as indigestion, so granular symptom characterization plus objective trends separate straightforward dyspepsia from complicated disease.

Typical patterns

• Burning or gnawing epigastric pain classically related to meals—duodenal discomfort may transiently ease with food then recurs when the duodenal bulb re-acidifies, while gastric pain can worsen with eating though overlap is common.
• Bloating, early satiety or post-prandial fullness when gastric outflow slows from oedema or scarring.
• Heartburn or reflux symptoms when inflammation sits near the cardia or when coexisting GERD is present.
• Nausea and dyspeptic discomfort that fluctuate with NSAID dosing cycles or missed acid-suppression doses.

High-risk or atypical cues

• Stereotyped chest pain—always entertain acute coronary syndrome, especially with diabetes or older age, before attributing pain to an ulcer alone.
• Painless presentations (particularly in older adults or anticoagulated patients) where the first sign is anaemia, syncope or coffee-ground vomiting.
• Alarm features: sustained vomiting, evidence of GI blood loss, iron deficiency, progressive unintentional weight loss or new dysphagia—any of these demand prompt investigation rather than dose stacking of antacids.
• Night pain that awakens from sleep or pain radiating through to the back should trigger surgical review for penetration or pancreatitis as local protocols dictate.

H. pylori remains the dominant infectious driver—urease-rich organisms disrupt mucus integrity and drive chronic active gastritis, progressing to ulceration when host and environmental cofactors align. Always pair eradication discussions with resistance-aware antibiotic stewardship and document penicillin allergy status before selecting regimens.

NSAIDs—including aspirin, ibuprofen-type agents and many over-the-counter analgesics—impair prostaglandin-mediated mucosal defence. Risk rises with higher doses, polypharmacy, concomitant anticoagulation or ibuprofen/aspirin combinations, older age and prior ulcer history. Glucocorticoids rarely ulcerate alone but magnify NSAID toxicity. Alcohol and smoking delay healing; ICU stress injury reflects splanchnic hypoperfusion in shock states.

Functional overlap with gastroesophageal reflux disease and esophagitis is common—patients may describe both retrosternal burning and epigastric ulcer pain. Clarify medication timing, NSAID exposure (including topical formulations) and recent steroid bursts when triaging exacerbations.

Clinical assessment

Combine medication reconciliation with a focused abdominal assessment and structured pain assessment. Quantify NSAID and aspirin exposure (including low-dose cardioprotective aspirin), alcohol units, prior eradication regimens, anticoagulant use and alarm symptoms. In selected low-risk outpatients, non-invasive H. pylori testing may precede endoscopy; older adults or anyone with alarm features should proceed directly to urgent endoscopy per NICE CG184-style triage.

Laboratory investigations

• Full blood count and iron studies for occult bleeding patterns.
• Renal and hepatic baseline tests before prolonged PPI courses or combination antibiotic therapy.
• Helicobacter pylori testing using stool antigen or urea breath assays when endoscopy is not first-line—observe PPI/antibiotic washout windows to avoid false negatives.
• Faecal occult blood testing may appear in primary-care bundles but never defers endoscopy when alarm symptoms coexist.

Imaging and endoscopy

Upper endoscopy (EGD) confirms the ulcer, obtains biopsies from gastric lesions, assigns Forrest grade during bleeding and enables hemostasis. CT or water-soluble contrast studies support perforation suspicion when examination suggests peritonitis. Plain chest radiography may demonstrate free subdiaphragmatic air when clinical suspicion is high.

Scoring systems

Apply Glasgow-Blatchford or Rockall tools when your hospital embeds them in upper GI bleed clerking to stratify early discharge versus continued inpatient observation—never delay resuscitation for the sake of scoring.

1. Stabilise and risk-stratify: Assess circulation, secure IV access, send baseline labs and group-and-save when bleeding is suspected; document orthostasis and conscious level.
2. Define the phenotype: Uncomplicated dyspepsia without alarms → non-invasive H. pylori testing plus planned PPI duration; alarm features or shock → urgent endoscopy pathway with high-dose IV PPI per protocol.
3. Target the driver: Eradicate H. pylori if present; stop culpable NSAIDs; add misoprostol or full-dose PPI gastroprotection when NSAIDs are indispensable; reconcile anticoagulant holds with cardiology.
4. Execute therapy: Triple, quadruple or bismuth-based salvage regimens follow local resistance patterns—pair amoxicillin-containing schedules with allergy checks and monitor for diarrhoea or rash.
5. Prove success: Confirm eradication ≥4 weeks post-antibiotics with stool antigen or breath testing off PPI for ~2 weeks when safe; repeat endoscopy shows healing of gastric ulcers.
6. Safety-net: Give explicit triggers for recurrent haematemesis, syncope, worsening pain, fever with rigid abdomen or inability to tolerate oral fluids.

↔On a small screen, swipe or scroll sideways to see the full table.

First-line management

• Acid suppression: Full-dose PPI for 4–8 weeks heals most ulcers—commonly pantoprazole, esomeprazole or equivalent dosed 30–60 minutes before breakfast; bleeding variants transition to high-dose IV regimens until oral therapy resumes.
• H. pylori eradication: Combine PPI with 2–3 antibiotics per local resistance data—amoxicillin, clarithromycin-, nitroimidazole- or bismuth-based salvage when macrolide resistance is suspected; emphasise completing the full course despite diarrhoea.
• NSAID-associated ulcers: Stop the offending drug when possible; if alternatives are impossible, add PPI ± misoprostol and repeat endoscopic surveillance for bleeding stigmata.
• Mucosal cytoprotection: Sucralfate can be adjunctive yet interacts with other orally administered drugs—stagger doses per pharmacy guidance.
• Step-down options: Famotidine or other H2 blockers support nocturnal breakthrough symptoms or PPI intolerance.

Bleeding-specific bundles

After endoscopic therapy of high-risk stigmata, administer guideline-defined high-dose IV PPI infusions for approximately 72 hours, then transition to oral therapy. Continue to monitor for rebleeding—repeat drops in haemoglobin or new tachycardia mandate senior review. Coordinate blood transfusion thresholds with the responsible clinician and document units/labs in parallel.

Surgical / rescue care

Failure of endoscopic hemostasis, visible vessel rebleed or perforated viscus pushes care toward surgery or angiographic embolisation depending on centre capability—maintain nil by mouth, broad antibiotics when perforation is proven and update families early.

Special populations

• Pregnancy: Align PPI and antibiotic choice with obstetric pharmacists; avoid tetracyclines and bismuth subsalicylate products.
• Renal impairment: Dose-adjust metronidazole or other renally cleared agents per local monographs.
• Older adults: Polypharmacy magnifies NSAID risk—explore topical analgesia, physiotherapy and short analgesic ladders before adding another ulcerogenic agent.

Operational expectations spanning ambulatory clinics, acute medical units and endoscopy recovery.

• Monitoring rhythm: Unstable bleeders need intensive observation with paired haemoglobin and vital-sign charts; stable eradication patients may move to weekly phone follow-up per local pathways.
• Medication timing: Coach once-daily PPI users to take doses before food; mismatch here is a leading reversible cause of stalled healing.
• Failure criteria: Worsening pain after 2 weeks of therapy, new anemia, vomiting blood or inability to maintain oral intake should trigger re-evaluation—not silent dose doubling.
• Interaction vigilance: Clarithromycin boosters raise statin and calcium-channel levels; nitroimidazoles clash with alcohol; line up pharmacist review when polypharmacy is heavy.
• MDT communication: Ensure surgeons, interventional radiologists and ICU teams receive Forrest grade, hemoglobin trajectory and anticoagulation status in every handoff.
• Documentation: Capture eradication regimen name, start date, adverse effects and planned test-of-cure date inside medication reconciliation fields.

• Upper GI bleeding with hemodynamic compromise and transfusion dependence.
• Perforation with peritonitis or pneumoperitoneum.
• Gastric outlet obstruction from inflammation, scarring or pyloric channel oedema.
• Penetration into adjacent organs with rising inflammatory markers and focal tenderness.
• Iron-deficiency anaemia from chronic occult blood loss.
• Recurrent ulcer after incomplete eradication or resumed NSAID exposure.

Clinician-facing prevention centres on eradicating H. pylori when diagnosed, avoiding unnecessary NSAIDs, co-prescribing PPI/misoprostol when analgesics are essential, and supporting smoking cessation programmes. In ICU environments, adhere to stress-ulcer prophylaxis algorithms so patients receive acid suppression only when evidence supports benefit.

Uncomplicated ulcers usually heal within weeks of acid suppression and cause removal; recurrent symptoms imply untreated H. pylori, ongoing NSAID exposure or alternative diagnoses. Bleeding episodes carry short-term mortality risk proportional to age, comorbidity and timeliness of endoscopic therapy—long-term outlook improves when secondary prophylaxis (eradication, PPI, NSAID cessation) is maintained.

Bedside monitoring checklist

• Hourly stool and emesis character documentation during active bleeds with trended shock index.
• Strict fluid balance when patients are nil by mouth with IV PPI infusions—watch peripheral lines for extravasation.
• Mouth care for intubated or nil-by-mouth patients to reduce ventilator-associated pneumonia risk.
• Fowler positioning when aspiration risk coincides with massive hematemesis—align with airway team if intubation planned.
• Pain scores reassessed after each intervention; new-onset rigidity out of proportion to analgesia demands urgent medical review.

Communication & safety netting

Use teach-back for eradication regimens: patients should articulate timing of each antibiotic relative to meals and which symptoms require ED return. Escalate language barriers to translation services rather than relying on family alone for high-risk medication teaching.

Trigger emergency activation when:

• Haematemesis, BRB vomiting or large-volume melena.
• Syncope, hypotension or resting tachycardia after suspected GI bleed.
• Sudden severe abdominal pain with guarding or rigid abdomen.
• Fever with confusion in an older patient on PPI therapy—consider sepsis from perforation.
• Inability to swallow saliva or persistent vomiting suggesting outlet obstruction.

Pre-alert receiving hospitals with vital signs, anticoagulant exposure, previous endoscopic therapy and most recent haemoglobin.

Nursing-priority lens (NCSBN Clinical Judgment Measurement Model): recognise cues → analyse cues → prioritise hypotheses → generate solutions → take safe action → evaluate outcomes. These NCLEX-style clinical judgment practice items practise Priority FIRST, SATA, deteriorating-trend interpretation, multi-patient triage, ordered response, matrix matching and cloze completion around H. pylori testing pitfalls, PPI and eradication bundles, endoscopic bleed pathways and perforation red flags—mirroring Clinical Judgment Measurement Model cues.